Dexcom, Inc. announced that it will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21-24, 2024, in Orlando. This year at ADA, Dexcom is presenting more data on Dexcom CGM use Among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin.

Additionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s. As the use of GLP-1s continues to grow, data continues to show people with Type 2 diabetes on GLP-1s are more likely to use CGM after starting the medication. Going beyond Type 2 diabetes, another study presented at ADA demonstrates Dexcom CGM is a valuable behavior modification tool for people with prediabetes.

In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider interactions. Dexcom further solidified its position as the industry leader in connectivity this morning with Insulet?s announcement commencing the launch of the Omnipod 5 with Dexcom G7. Beginning, new Omnipod 5 users can experience the benefits of the only tubeless AID system connected to Dexcom G7, the most accurate CGM7 powering AID systems. Dexcom G7 will be available for existing Omnipod 5 users in the U.S. later this year.

Dexcom CGM currently connects to more AID pump options than any other CGM brand in the U.S.; the iLet Bionic Pancreas insulin pump, the Tandem pump portfolio (Tandem Mobi and t:slim X2 insulin pumps), and now Omnipod 5. For those seeking more information about the recent integration of Dexcom G7 and the Tandem Mobi insulin pump, there will be an evening education event during ADA on June 22, 2024, from 6-8 p.m.Registration is open to U.S. healthcare provider attendees. With hundreds of thousands of users now connected to insulin pumps, pens and digital health apps, Dexcom is the undisputed leader in CGM connectivity.